|
MechanismIL-21 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Placebo-Controlled, Double-blind, Multiple Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of SRK-001 in Healthy Participants
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics (PK) of SRK-001 in Healthy Participants.
A Randomized, Placebo-Controlled, Double-blind, Multiple Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of SRK-001 in Healthy Participants. - Multiple Dose Study on Safety, Tolerability, and PK of SRK-001
100 Clinical Results associated with Sarkana Pharma, Inc.
0 Patents (Medical) associated with Sarkana Pharma, Inc.
100 Deals associated with Sarkana Pharma, Inc.
100 Translational Medicine associated with Sarkana Pharma, Inc.